B-intervention	0	11	Gemcitabine
I-intervention	12	16	plus
I-intervention	17	27	Paclitaxel
O	28	34	versus
B-control	35	45	Paclitaxel
O	46	57	monotherapy
O	58	60	in
B-eligibility	61	69	patients
I-eligibility	70	74	with
I-eligibility	75	85	metastatic
I-eligibility	86	92	breast
I-eligibility	93	99	cancer
I-eligibility	100	103	and
I-eligibility	104	109	prior
I-eligibility	110	123	anthracycline
I-eligibility	124	133	treatment
O	133	134	.

O	135	138	The
O	139	148	objective
O	149	151	of
O	152	156	this
O	157	162	phase
O	163	166	III
O	167	173	global
O	174	179	study
O	180	183	was
O	184	186	to
O	187	194	compare
O	195	198	the
O	199	207	efficacy
O	208	210	of
O	211	222	gemcitabine
O	223	227	plus
O	228	238	paclitaxel
O	239	240	(
O	240	242	GT
O	242	243	)
O	244	250	versus
O	251	261	paclitaxel
O	262	264	in
O	265	273	patients
O	274	278	with
O	279	287	advanced
O	288	294	breast
O	295	301	cancer
O	301	302	.

O	303	305	It
O	306	309	was
O	310	318	designed
O	319	321	as
O	322	323	a
O	324	331	pivotal
O	332	337	study
O	338	341	for
O	342	345	the
O	346	354	approval
O	355	357	of
O	358	359	G
O	360	363	for
O	364	365	a
O	366	372	breast
O	373	379	cancer
O	380	389	treatment
O	390	400	indication
O	400	401	.

O	402	410	Patients
O	411	414	who
O	415	423	relapsed
O	424	429	after
O	430	438	adjuvant
O	439	453	anthracyclines
O	454	458	were
O	459	467	randomly
O	468	476	assigned
O	477	479	to
O	480	491	gemcitabine
O	491	492	,
O	492	493	1
O	493	494	,
O	494	497	250
O	498	500	mg
O	500	501	/
O	501	502	m
O	502	503	(
O	503	504	2
O	504	505	)
O	506	510	days
O	511	512	1
O	513	516	and
O	517	518	8
O	519	523	plus
O	524	534	paclitaxel
O	534	535	,
O	536	539	175
O	540	542	mg
O	542	543	/
O	543	544	m
O	544	545	(
O	545	546	2
O	546	547	)
O	548	550	on
O	551	554	day
O	555	556	1
O	556	557	;
O	558	560	or
O	560	561	,
O	562	564	to
O	565	575	paclitaxel
O	576	578	at
O	579	583	same
O	584	588	dose
O	589	591	on
O	592	595	day
O	596	597	1
O	598	599	(
O	599	603	both
O	604	608	arms
O	609	621	administered
O	622	627	every
O	628	630	21
O	631	635	days
O	635	636	,
O	637	646	unblinded
O	646	647	)
O	647	648	.

O	649	652	The
O	653	660	primary
O	661	664	end
O	665	670	point
O	671	674	was
B-outcome-Measure	675	682	overall
I-outcome-Measure	683	691	survival
I-outcome-Measure	692	693	(
I-outcome-Measure	693	695	OS
I-outcome-Measure	695	696	)
O	697	700	and
O	701	710	secondary
O	711	714	end
O	715	721	points
O	722	726	were
B-outcome-Measure	727	731	time
I-outcome-Measure	732	734	to
I-outcome-Measure	735	746	progression
I-outcome-Measure	747	748	(
I-outcome-Measure	748	751	TTP
I-outcome-Measure	751	752	)
O	752	753	,
B-outcome-Measure	754	762	response
I-outcome-Measure	763	767	rate
I-outcome-Measure	768	769	(
I-outcome-Measure	769	771	RR
I-outcome-Measure	771	772	)
O	772	773	,
B-outcome-Measure	774	785	progression
I-outcome-Measure	785	786	-
I-outcome-Measure	786	790	free
I-outcome-Measure	791	799	survival
O	799	800	,
B-outcome-Measure	801	809	response
I-outcome-Measure	810	818	duration
O	818	819	,
O	820	823	and
B-outcome-Measure	824	832	toxicity
O	832	833	.

O	834	838	This
O	839	844	final
O	845	847	OS
O	848	856	analysis
O	857	860	was
O	861	868	planned
O	869	871	at
O	872	875	380
O	876	882	deaths
O	882	883	.

O	884	885	A
O	886	891	total
O	892	894	of
B-intervention-participants	895	898	266
O	899	907	patients
O	908	912	were
O	913	921	randomly
O	922	930	assigned
O	931	933	to
O	934	936	GT
O	937	940	and
B-control-participants	941	944	263
O	945	947	to
O	948	958	paclitaxel
O	958	959	.

B-outcome	960	966	Median
I-outcome	967	975	survival
O	976	978	on
O	979	981	GT
O	982	985	was
B-iv-cont-median	986	988	18
I-iv-cont-median	988	989	.
I-iv-cont-median	989	990	6
I-iv-cont-median	991	997	months
O	998	1004	versus
B-cv-cont-median	1005	1007	15
I-cv-cont-median	1007	1008	.
I-cv-cont-median	1008	1009	8
I-cv-cont-median	1010	1016	months
O	1017	1019	on
O	1020	1030	paclitaxel
O	1031	1032	(
O	1032	1035	log
O	1035	1036	-
O	1036	1040	rank
O	1041	1042	P
O	1043	1044	=
O	1045	1046	.
O	1047	1051	0489
O	1051	1052	)
O	1052	1053	,
O	1054	1058	with
O	1059	1061	an
O	1062	1070	adjusted
O	1071	1074	Cox
O	1075	1081	hazard
O	1082	1087	ratio
O	1088	1090	of
O	1091	1092	0
O	1092	1093	.
O	1093	1095	78
O	1096	1097	(
O	1097	1099	95
O	1099	1100	%
O	1101	1103	CI
O	1103	1104	,
O	1105	1106	0
O	1106	1107	.
O	1107	1109	64
O	1110	1112	to
O	1113	1114	0
O	1114	1115	.
O	1115	1117	96
O	1117	1118	;
O	1119	1120	P
O	1121	1122	=
O	1123	1124	.
O	1124	1128	0187
O	1128	1129	)
O	1129	1130	.

O	1131	1134	The
B-outcome	1135	1138	TTP
O	1139	1142	was
O	1143	1149	longer
O	1150	1151	(
B-iv-cont-median	1151	1152	6
I-iv-cont-median	1152	1153	.
I-iv-cont-median	1153	1155	14
O	1156	1157	v
B-cv-cont-median	1158	1159	3
I-cv-cont-median	1159	1160	.
I-cv-cont-median	1160	1162	98
I-cv-cont-median	1163	1169	months
O	1169	1170	;
O	1171	1174	log
O	1174	1175	-
O	1175	1179	rank
O	1180	1181	P
O	1182	1183	=
O	1184	1185	.
O	1185	1189	0002
O	1189	1190	)
O	1191	1194	and
O	1195	1198	the
B-outcome	1199	1201	RR
O	1202	1205	was
O	1206	1212	better
O	1213	1214	(
B-iv-bin-percent	1214	1216	41
I-iv-bin-percent	1216	1217	.
I-iv-bin-percent	1217	1218	4
I-iv-bin-percent	1218	1219	%
O	1220	1221	v
B-cv-bin-percent	1222	1224	26
I-cv-bin-percent	1224	1225	.
I-cv-bin-percent	1225	1226	2
I-cv-bin-percent	1226	1227	%
O	1227	1228	;
O	1229	1230	P
O	1231	1232	=
O	1233	1234	.
O	1234	1238	0002
O	1238	1239	)
O	1240	1242	on
O	1243	1245	GT
O	1245	1246	.

O	1247	1252	There
O	1253	1256	was
O	1257	1261	more
B-outcome	1262	1267	grade
I-outcome	1268	1269	3
I-outcome	1270	1272	to
I-outcome	1273	1274	4
I-outcome	1275	1286	neutropenia
O	1287	1289	on
O	1290	1292	GT
O	1293	1296	and
B-outcome	1297	1302	grade
I-outcome	1303	1304	2
I-outcome	1305	1307	to
I-outcome	1308	1309	4
I-outcome	1310	1317	fatigue
I-outcome	1318	1321	and
I-outcome	1322	1332	neuropathy
O	1333	1337	were
O	1338	1346	slightly
O	1347	1351	more
O	1352	1361	prevalent
O	1362	1364	on
O	1365	1367	GT
O	1367	1368	.

O	1369	1373	This
O	1374	1379	phase
O	1380	1383	III
O	1384	1389	study
O	1390	1399	documents
O	1400	1401	a
O	1402	1406	role
O	1407	1410	for
O	1411	1422	gemcitabine
O	1423	1425	in
O	1426	1434	advanced
O	1435	1441	breast
O	1442	1448	cancer
O	1449	1454	after
O	1455	1468	anthracycline
O	1468	1469	-
O	1469	1474	based
O	1475	1483	adjuvant
O	1484	1491	therapy
O	1491	1492	.

O	1493	1496	The
O	1497	1504	results
O	1505	1514	establish
O	1515	1517	GT
O	1518	1520	as
O	1521	1522	a
O	1523	1533	reasonable
O	1534	1540	choice
O	1541	1544	for
O	1545	1550	women
O	1551	1554	who
O	1555	1562	require
O	1563	1576	cytoreduction
O	1577	1581	with
O	1582	1592	manageable
O	1593	1603	toxicities
O	1604	1607	and
O	1608	1616	validate
O	1617	1624	ongoing
O	1625	1632	testing
O	1633	1635	of
O	1636	1638	GT
O	1639	1641	in
O	1642	1645	the
O	1646	1654	adjuvant
O	1655	1662	setting
O	1662	1663	.
